NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

成纖維細胞生長因子受體 (FGFR) 抑製劑的全球市場機會和臨床試驗洞察 (2026)

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026

出版商 KuicK Research 商品編碼 1021730
出版日期 內容資訊 英文 195 Pages
商品交期: 最快1-2個工作天內
價格
成纖維細胞生長因子受體 (FGFR) 抑製劑的全球市場機會和臨床試驗洞察 (2026) Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026
出版日期: 2021年08月09日內容資訊: 英文 195 Pages
簡介

到 2026 年,成纖維細胞生長因子受體 (FGFR) 抑製劑的全球市場預計將達到 40 億美元。近期癌症領域小分子療法的突破,在提高癌症生存率方面取得了顯著成果。

FGFR抑製劑是一類小分子受體激□抑製劑,廣泛應用於膀胱癌、乳腺癌、肺癌、胃癌、淋巴瘤、骨髓瘤等多種癌症的治療,被認為是其中之一。先進的抗癌藥物。 FGFR抑製劑在短時間內克服了所有挑戰,並達到了對該治療的有用性進行高度評價的階段。

本報告調查了全球成纖維細胞生長因子受體 (FGFR) 抑製劑市場、FGFR 抑製劑在癌症治療中的作用、市場規模和預測以及批准的 FGFR 抑製劑。它提供了有關臨床和營銷、使用/劑量/藥物的信息價格考慮因素,按公司、國家、階段和患者人口統計、競爭形勢和主要公司簡介進行的綜合臨床試驗概述。

目錄

第一章 FGFR 抑製劑介紹

  • 概述
  • FGFR 抑製劑的進化

第 2 章 FGFR 抑製劑-作用機制

第 3 章 FGFR 抑製劑在癌症治療中的作用

  • AZD4547
  • E7090
  • 德比奧 1347
  • 富巴替尼
  • 洛格替尼
  • 德拉贊替尼
  • RLY-4008
  • CPL304110

第 4 章全球 FGFR 抑製劑市場分析

  • 當前市場情景
  • 未來的市場機會

第 5 章區域:全球 FGFR 抑製劑市場機遇

  • 美國
  • 歐洲
  • 日本
  • 其他領域

癌症第 6 章:全球 FGFR 抑製劑市場的機遇

  • 膽管癌
  • 尿路上皮癌
  • 淋巴瘤
  • 肺癌

第 7 章 Barbersa 首次批准的 FGFR 抑製劑 (2019)

  • 概述
  • 專利洞察

第 8 章 Barbersa-商業可用性、劑量和價格分析

第 9 章 Pemazia-第二次批准的 FGFR 抑製劑 (2020)

  • 概述
  • 專利洞察

第 10 章 Pemazaia-商業信息

  • 用量及價格分析
  • 銷售分析

第 11 章 Torseltic-第三次批准的 FGFR 抑製劑 2021

  • 概述
  • 專利洞察

第 12 章 Torseltic 的商業可用性、劑量和價格分析

第 13 章全球銷售預測-2021 年至 2026 年

  • 貝爾維拉
  • 佩馬扎亞
  • 扭轉

第 14 章 FGFR 抑製劑-正在進行的臨床試驗

  • 按階段
  • 按開發狀態
  • 按地區

第 15 章臨床試驗中的 Global-FGFR 抑製劑

  • 調查
  • 臨床前
  • 第一階段
  • 第一/第二階段
  • 第二階段
  • 第二/第三階段
  • 第三階段
  • 預註冊

第 16 章對市售 FGFR 抑製劑的臨床見解

第 17 章全球 FGFR 抑製劑市場動態

  • 全球 FGFR 抑製劑市場的增長因素
  • 全球 FGFR 抑製劑市場的挑戰

第 18 章全球 FGFR 抑製劑市場的未來展望

第19章競爭形勢

  • Amgen
  • Astex Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Blueprint Medicine
  • Boehringer Ingelheim International
  • Bristol Mayer Squibb
  • Incyte Corporation
  • Janssen Pharmaceuticals
  • Novartis International
  • Pfizer Inc
  • Roche
  • Taiho
  • TransThera Biosciences
目錄

"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026" Report Highlights:

  • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026
  • Role of FGFR Inhibitors in Cancer Therapy
  • Global FGFR Market Assessment (US$) by Region & Cancer Type
  • Clinical & Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre & Truseltiq)
  • Dosage & Drug Price Insight on Approved FGFR Inhibitors
  • Comprehensive Clinical Trials Insight by Company, Country, Phase & Patient Segment: 53 Drugs in Trials

Recent breakthrough with respect to small molecule based therapy in the oncology segment has set up remarkable achievements in terms of improving the cancer survival rate. The FGFR inhibitors are considered as one of advanced anticancer therapy, which belongs to the class of receptor kinase inhibiting small molecules and now widely accepted for the treatment of various cancer types including bladder cancer, breast cancer, lung cancer gastric cancer, lymphoma, myeloma etc. In a short period of time, FGFR inhibitors has made its way through all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised.

The mutation or over expression of FGFR makes them ideal target for management of cancer and most of the researchers exploring the therapeutic potential of this class concluded the beneficial effects of this approach. Further, the FGFR alterations are also observed in rare cancers and hence this approach has potential to play a crucial role in the management of untreatable rare types of cancers. Currently, the market of FGFR inhibitors is at nascent stage, which is driven by the sales of 3 approved products of this class i.e. Balversa, Pemazyre and Truseltiq. Balversa is recommended for management of bladder cancer while Pemazyre and Truseltiq are recommended for the management of rare cancer termed as Cholangiocarcinoma. Many new drugs of this class are also believed to get orphan designation in upcoming years, which further boost the market size of this segment.

Balversa is expected to lead the market segment as its sales value is believed to increase exponentially after its approval in the leading regions including Europe and Japan. The estimated market size of FGFR inhibitor is about US$ 100 Million in year 2020 and it is believed to grow with CAGR of more than 80% during the next 6 years as most of the market related factors are indicating towards the increasing acceptance of this segment in near future. Further, US will lead FGFR market due to availability of huge cancer burden and leading pharmaceutical companies. The drug approval process is now simplified in US due to availability of all the three drugs of this class and hence most of the new FGFR inhibitors will first get approval in this region.

With an aim of improving the market penetrability and commercialization of FGFR inhibitors, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of developing companies, which will increase the market size of this novel segment in regions such as Asia-Pacific, Middle-East and Latin America. The leading pharmaceutical companies working in this sector are Amgen, Astem pharma, AstraZenca, Bayer, BMS, Incyte, Roche, Taiho, Janssen pharmaceuticals, Novartis etc. while many other companies are working on FGFR inhibitors in preclinical studies.

"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026" report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to FGFR inhibitors market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for FGR inhibitors drugs.

Table of Contents

1. Introduction to FGFR Inhibitors

  • 1.1 Overview
  • 1.2 Evolution of FGFR Inhibitors

2. FGFR Inhibitors - Mechanism of Action

3. Role of FGFR Inhibitors in Cancer Therapy

  • 3.1 AZD4547
  • 3.2 E7090
  • 3.3 Debio 1347
  • 3.4 Futibatinib
  • 3.5 Rogaratinib
  • 3.6 Derazantinib
  • 3.7 RLY-4008
  • 3.8 CPL304110

4. Global FGFR Inhibitor Market Analysis

  • 4.1 Current Market Scenario
  • 4.2 Future Market Opportunity

5. Global FGFR Inhibitors Market Opportunity by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 Rest of World

6. Global FGFR Inhibitors Market Opportunity by Cancer

  • 6.1 Cholangiocarcinoma
  • 6.2 Urothelial Carcinoma
  • 6.3 Lymphoma
  • 6.4 Lung Cancer

7. Balversa - First Approved FGFR Inhibitor 2019

  • 7.1 Overview
  • 7.2 Patent Insight

8. Balversa - Comercial Availability, Dosage & Price Analysis

9. Pemazyre - Second Approved FGFR Inhibitor 2020

  • 9.1 Overview
  • 9.2 Patent Insight

10. Pemazyre - Commercial Information

  • 10.1 Dosage & Price Analysis
  • 10.2 Sales Analysis

11. Truseltiq - Third Approved FGFR Inhibitor Drug 2021

  • 11.1 Overview
  • 11.2 Patent Insight

12. Truseltiq - Commercial Availability, Dosage & Price Analysis

13. Global Sales Forecast - 2021 Till 2026

  • 13.1 Belvesra
  • 13.2 Pemazyre
  • 13.3 Truseltiq

14. FGFR Inhibitors - Ongoing Clinical Trials

  • 14.1 By Phase
  • 14.2 By Development Status
  • 14.3 By Region

15. Global - FGFR Inhibitors in Clinical Trials

  • 15.1 Research
  • 15.2 Preclinical
  • 15.3 Phase-I
  • 15.4 Phase-I/II
  • 15.5 Phase-II
  • 15.6 Phase-II/III
  • 15.7 Phase-III
  • 15.8 Preregistration

16. Marketed FGFR Inhibitors Drugs Clinical Insight

17. Global FGFR Inhibitors Market Dynamics

  • 17.1 Drivers for Global FGFR Inhibitors Market
  • 17.2 Global FGFR Inhibitors Market Challenges

18. Global FGFR Inhibitors Market Future Outlook

19. Competitive Landscape

  • 19.1 Amgen
  • 19.2 Astex Pharmaceuticals
  • 19.3 AstraZeneca
  • 19.4 Bayer
  • 19.5 Blueprint Medicine
  • 19.6 Boehringer Ingelheim International
  • 19.7 Bristol Mayer Squibb
  • 19.8 Incyte Corporation
  • 19.9 Janssen Pharmaceuticals
  • 19.10 Novartis International
  • 19.11 Pfizer Inc
  • 19.12 Roche
  • 19.13 Taiho
  • 19.14 TransThera Biosciences

List of Tables

  • Table 6-1: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
  • Table 6-2: Global - Estimated Adoption Rates for Cholangiocarcinoma Targeting FGFR Inhibitors, 2021-2026
  • Table 6-3: Global - Estimated Adoption Rates for NHL Targeting FGFR Inhibitors, 2021-2026
  • Table 6-4: Global - Estimated Adoption Rates for Lung Cancer Targeting FGFR Inhibitors, 2021-2026

List of Figures

  • Figure 1-1: History of FGFR Inhibitors
  • Figure 2-1: General Mechanism of FGFR Inhibitors
  • Figure 2-2: Balversa - Mechanism of Action Against Urothelial Cancer
  • Figure 2-3: Mechanism of Pemazyre & Truseltiq Against Cholangiocarcinoma
  • Figure 3-1: FGFR Mutational Frequency by Cancer Type (%)
  • Figure 3-2: Roles of FGFR Inhibitors in Cancer
  • Figure 3-3: Investigational FGFR Inhibitors
  • Figure 3-4: E7090 Phase II Trial - Study Initiation & Completion Year
  • Figure 3-5: E7090 Phase II Fortune Trial - Study Initiation & Completion Year
  • Figure 3-6: E7090 Phase I Trial - Study Initiation & Completion Year
  • Figure 3-7: Debio 1347 Phase II Trial - Study Initiation & Completion Year
  • Figure 3-8: Debio 1347 Phase I-II Trial - Study Initiation & Completion Year
  • Figure 3-9: Futibatinib Phase II Trial - Study Initiation & Completion Year
  • Figure 3-10: Futibatinib & Pembrolizumab Phase II Trial - Study Initiation & Completion Year
  • Figure 3-11: Futibatinib & Binimetinib Phase I-II Trial - Study Initiation & Completion Year
  • Figure 3-12: Futibatinib & Fulvestrant Phase I-II Trial - Study Initiation & Completion Year
  • Figure 3-13: Rogaratinib Phase II Trial for NSCLC - Study Initiation & Completion Year
  • Figure 3-14: Rogaratinib Phase II Trial for GIST - Study Initiation & Completion Year
  • Figure 3-15: Rogaratinib Phase I-II Trial - Study Initiation & Completion Year
  • Figure 3-16: Rogaratinib Phase I Trial - Study Initiation & Completion Year
  • Figure 3-17: Derazantinib Phase II Trial - Study Initiation & Completion Year
  • Figure 3-18: Derazantinib Phase I-II Trial - Study Initiation & Completion Year
  • Figure 3-19: Derazantinib/Atezolizumab Phase II Trial - Study Initiation & Completion Year
  • Figure 3-20: RLY4008 Phase I Trial - Study Initiation & Completion Year
  • Figure 3-21: CPL304110 Phase I Trial - Study Initiation & Completion Year
  • Figure 4-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
  • Figure 4-2: Global - Number of Cancer Deaths (Million), 2020, 2025 & 2030
  • Figure 4-3: Global - FGFR Inhibitors Market Opportunity (US$ Million), 2020-2026
  • Figure 4-4: Global - Cancer Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-5: Global - FGFR Inhibitors Market by Product (%) 2026
  • Figure 5-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-2: US - FGFR Inhibitors Market Opportunity (US$ Million), 2020-2026
  • Figure 5-3: US - FGFR Inhibitors Market by Product (%) 2026
  • Figure 5-4: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-5: Europe - FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
  • Figure 5-6: Europe - FGFR Inhibitors Market by Product (%) 2026
  • Figure 5-7: Japan - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
  • Figure 5-8: Japan - FGFR Inhibitors Market Opportunity (US$ Million), 2022-2026
  • Figure 5-9: Japan - FGFR Inhibitors Market by Product (%) 2026
  • Figure 5-10: ROW - FGFR Inhibitors Market Opportunity (US$ Million), 2022-2026
  • Figure 5-11: ROW - FGFR Inhibitors Market by Product (%), 2026
  • Figure 6-1: Global - Number of Cholangiocarcinoma Cases, 2021-2026
  • Figure 6-2: Global - Cholangiocarcinoma Targeting FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
  • Figure 6-3: Global - Number of Urotheluial Carcinoma Cases, 2021-2026
  • Figure 6-4: Global - Urothelial Carcinoma Targeting FGFR Inhibitors Market Opportunity (US$ Million), 2021-2026
  • Figure 6-5: Global - Number of NHL Cases, 2021-2026
  • Figure 6-6: Global - NHL Targeting FGFR inhibitors Market Opportunity (US$ Million), 2023 - 2026
  • Figure 6-7: Global - Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026
  • Figure 6-8: Global - Lung Cancer Targeting FGFR inhibitors Market Opportunity (US$ Million), 2022 - 2026
  • Figure 7-1: Balversa - Patent Issue & Expiration Year
  • Figure 8-1: Balversa - Price for 56 Tablets Supply & Price per Unit of 3mg Tablet (US$), July'2021
  • Figure 8-2: Balversa - Price for 84 Tablets Supply & Price per Unit of 3mg Tablet (US$), July'2021
  • Figure 8-3: Balversa - Price for 28 Tablets Supply & Price per Unit of 4mg Tablet (US$), July'2021
  • Figure 8-4: Balversa - Price for 56 Tablets Supply & Price per Unit of 4mg Tablet (US$), July'2021
  • Figure 8-5: Balversa - Price for 28 Tablets Supply & Price per Unit of 5mg Tablet (US$), July'2021
  • Figure 8-6: Balversa - Initial & Maintenance Dose (mg/Day)
  • Figure 8-7: Balversa - Initial Dose After Reduction (mg/Day)
  • Figure 8-8: Balversa - Maintenance Dose After Reduction (mg/Day)
  • Figure 9-1: Pemazyre - Approval Year by Region
  • Figure 9-2: Pemazyre - Patent Issue & Expiration Year
  • Figure 10-1: US - Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US$), July'2021
  • Figure 10-2: Europe - Price for 14 Tablets Supply & Price per Unit of Various Doses of Pemazyre (US$), July'2021
  • Figure 10-3: Pemazyre - Duration of Single Treatment Cycle by Phase (days)
  • Figure 10-4: Pemazyre - Initial & Reduced Dose (mg/day)
  • Figure 10-5: Global - Pemazyre Quarterly Sales (US$ Million), 2020
  • Figure 11-1: Truseltiq - FDA Approval & Orphan Designation Year
  • Figure 11-2: Truseltiq - Patent Issue & Expiration Year
  • Figure 12-1: Truseltiq - Price for 42 Capsules Supply & Price per Unit of Dose 125mg (US$), August'2021
  • Figure 12-2: Truseltiq - Price for 42 Capsules Supply & Price per Unit of Dose 50mg (US$), August'2021
  • Figure 12-3: Truseltiq - Price for 63 Capsules Supply & Price per Unit of Dose 75mg (US$), August'2021
  • Figure 12-4: Truseltiq - Price for 21 Capsules Supply & Price per Unit of Dose 100mg (US$), August'2021
  • Figure 12-5: Truseltiq - Duration of Single Treatment Cycle by Phase (days)
  • Figure 12-6: Truseltiq - Initial & Reduced Dose (mg/day)
  • Figure 13-1: Global - Balversa Sales Forecast (US$ Million), 2021-2026
  • Figure 13-2: US - Balversa Sales Forecast (US$ Million), 2021-2026
  • Figure 13-3: Europe - Balversa Sales Forecast (US$ Million), 2022-2026
  • Figure 13-4: Japan - Balversa Sales Forecast (US$ Million), 2022-2026
  • Figure 13-5: ROW - Balversa Sales Forecast (US$ Million), 2022-2026
  • Figure 13-6: Global - Pemazyre Sales Forecast (US$ Million), 2021-2026
  • Figure 13-7: US - Pemazyre Sales Forecast (US$ Million), 2021-2026
  • Figure 13-8: Europe - Pemazyre Sales Forecast (US$ Million), 2022-2026
  • Figure 13-9: Japan - Pemazyre Sales Forecast (US$ Million), 2022-2026
  • Figure 13-10: ROW - Pemazyre Sales Forecast (US$ Million), 2022-2026
  • Figure 13-11: Global - Truseltiq Sales Forecast (US$ Million), 2021-2026
  • Figure 13-12: US - Truseltiq Sales Forecast (US$ Million), 2021-2026
  • Figure 13-13: Europe - Truseltiq Sales Forecast (US$ Million), 2022-2026
  • Figure 13-14: Japan - Truseltiq Sales Forecast (US$ Million), 2022-2026
  • Figure 13-15: ROW - Truseltiq Sales Forecast (US$ Million), 2022-2026
  • Figure 14-1: Pemazyre - Number of Clinical Trials by Phase, July'2021
  • Figure 14-2: Pemazyre - Number of Clinical Trials by Phase, July'2021
  • Figure 14-3: Pemazyre - Number of Clinical Trials by Development Status, July'2021
  • Figure 14-4: Pemazyre - Number of Clinical Trials by Development Status (%), July'2021
  • Figure 14-5: Pemazyre - Number of Clinical Trials by Region, July'2021
  • Figure 15-1: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Phase, 2021 till 2026
  • Figure 15-2: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Company, 2021 till 2026
  • Figure 15-3: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Patient Segment, 2021 till 2026
  • Figure 15-4: Global - Number of FGFR Inhibitors Drugs in Clinical Trials by Country, 2021 till 2026
  • Figure 17-1: Global FGFR Market Drivers
  • Figure 17-2: Challenges for Global FGFR Inhibitors Market
  • Figure 17-3: US - Annual Treatment Cost Comparison Using Various Drugs (US$), August'2021